WO2024103126A1 - Ligands de tspo - Google Patents

Ligands de tspo Download PDF

Info

Publication number
WO2024103126A1
WO2024103126A1 PCT/AU2023/051173 AU2023051173W WO2024103126A1 WO 2024103126 A1 WO2024103126 A1 WO 2024103126A1 AU 2023051173 W AU2023051173 W AU 2023051173W WO 2024103126 A1 WO2024103126 A1 WO 2024103126A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
ealkyl
solvate
tautomer
Prior art date
Application number
PCT/AU2023/051173
Other languages
English (en)
Inventor
Jonathan DANON
Michael Kassiou
Greta SOHLER
Renee SOKIAS
Tristan Reekie
Eryn Werry
Original Assignee
The University Of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022903474A external-priority patent/AU2022903474A0/en
Application filed by The University Of Sydney filed Critical The University Of Sydney
Publication of WO2024103126A1 publication Critical patent/WO2024103126A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), éventuellement radiomarqués avec un radionucléide, ainsi que des sels, solvates, tautomères, N-oxydes, stéréoisomères et/ou polymorphes pharmaceutiquement acceptables de ceux-ci. L'invention concerne également des méthodes d'utilisation des composés de formule (I) pour détecter une protéine translocatrice (18 kDa) (TSPO). L'invention concerne en outre des méthodes d'utilisation des composés de formule (I) pour diagnostiquer et/ou traiter une maladie, un trouble ou un état associé à la TSPO.
PCT/AU2023/051173 2022-11-18 2023-11-17 Ligands de tspo WO2024103126A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022903474A AU2022903474A0 (en) 2022-11-18 TSPO ligands
AU2022903474 2022-11-18

Publications (1)

Publication Number Publication Date
WO2024103126A1 true WO2024103126A1 (fr) 2024-05-23

Family

ID=91083417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2023/051173 WO2024103126A1 (fr) 2022-11-18 2023-11-17 Ligands de tspo

Country Status (1)

Country Link
WO (1) WO2024103126A1 (fr)

Similar Documents

Publication Publication Date Title
JP7299837B2 (ja) 化合物、組成物、および使用方法
CA3001857A1 (fr) Composes, compositions et methodes d'utilisation contre des granules de stress
CA3037728A1 (fr) Composes de 4,6-indazole et methodes de modulation ido et tdo, et indications connexes
JP2010518026A (ja) ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
BR112016026951B1 (pt) Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas
AU2016354661B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
BR112018075736B1 (pt) Composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
WO2020122093A1 (fr) Composé hétérocyclique
WO2020122092A1 (fr) Composé hétérocyclique
AU2017270858A1 (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
JP2020535208A (ja) 新規な複素環式化合物
JPH02138266A (ja) 6‐フェニル‐3‐(ピペラジニルアルキル)‐2,4(1h,3h)‐ピリミジンジオン誘導体
BRPI0911659B1 (pt) composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
JP6033788B2 (ja) 置換されたメチルアミン、セロトニン5−ht6受容体アンタゴニスト、製造のための方法及びその使用
JP2004512364A (ja) 中枢神経系疾患の治療のためのスルホンアミド
WO2024103126A1 (fr) Ligands de tspo
US20240067654A1 (en) Oxytocin receptor modulators
WO2016046404A1 (fr) Pyrazoloquinazolinones et pyrroloquinazolinones substituées en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate du groupe ii
CN113666853B (zh) 可用作RORγ调节剂的联芳基类化合物
ES2256506T3 (es) Agonistas triciclicos del receptor crf.
JP2018501282A (ja) チアゾール誘導体の製造方法
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
WO2021132311A1 (fr) Dérivé amide d'acide aliphatique
BR112019019740A2 (pt) compostos heterocíclicos substituídos como moduladores alostéricos de receptores de glutamato metabotrópicos de grupo ii
CN109111418B (zh) 一类2,3-二氢-1H-茚-4-磺酰胺RORγ调节剂及其用途